Village Farms International, Inc.

What they do

The company produces and sells branded and wholesale cannabis in Canada (Pure Sunfarms, Rose LifeScience) and the Netherlands (Village Farms International B.V.), operates a U.S. hemp-derived CBD business (Balanced Health / CBDistillery), and generates renewable natural gas royalties from a Vancouver landfill project. It also grows tomatoes in British Columbia greenhouses, sold under the Village Farms Fresh brand, and holds Texas greenhouse facilities for potential future cannabis production.

Revenue drivers

• Canadian Cannabis — Largest segment, selling dried flower, pre-rolls, vapes and other products to provincial buyers and consumers; top five overall market share in Canada and top 10 in all major categories.
• International Exports — EU-GMP certified medical cannabis exports to Germany, Australia, Israel, UK, and New Zealand; record Q2 2026 export sales of $20.9 million, up 74% year-over-year and 43% sequentially.
• U.S. CBD / Hemp — Balanced Health sells CBD and other cannabinoid wellness products via the CBDistillery e-commerce platform; a secondary revenue stream.
• Produce (Village Farms Fresh) — Greenhouse-grown tomatoes sold to grocery chains and food distributors; contributes revenue but now operates as a non-reportable segment after its privatization in 2025.

Recent performance

For Q2 2026, consolidated net sales were $64.0 million, up 27% sequentially and 7% year-over-year. Cannabis net sales were $53.5 million (up 5% YoY) with gross margin improving to 51% from 42%. Net income was $7.1 million ($0.06 per share) and operating cash flow was $8.9 million. The company reported its fifth consecutive quarter of positive net income, with full-year 2025 net income of $32.4 million on revenue of $215.9 million.

Strategy

The company is unifying its cannabis operations under a single reportable segment to gain efficiencies and better align resources. It is expanding international markets, particularly in Europe, leveraging its EU-GMP certified Delta 3 facility and Netherlands licenses. Investments in Delta 2 greenhouse expansion and Netherlands capacity are nearly complete, with full production expected by end of Q1 2027 and mid-2027 respectively. Management continues to evaluate organic and acquisitive growth opportunities globally while maintaining a strong cash balance of $73 million.

Risks

• Regulatory and legal risk — Cannabis remains federally illegal in the U.S., and international expansion depends on evolving and uncertain legal frameworks in target markets.
• Market competition and pricing — Intense competition in Canadian adult-use market could pressure prices and market share despite the company's low-cost position.
• Operational execution risk — Ramping Netherlands operations to full capacity and completing Delta 2 expansion are subject to construction, licensing, and cultivation performance risks.
• Dependence on export markets — A significant portion of international sales relies on Europe, particularly Germany, where regulatory changes or supply competition could impact volumes and margins.

Outlook

Management expects continued profitable growth driven by record harvest yields and lower production costs in Canada, plus international expansion into new European jurisdictions later this year. Netherlands operations are targeted to reach full production capacity by Q1 2027, and the Delta 2 expansion is on track for a 40-tonne annual run rate by mid-2027. The company expects to grow its cash balance from positive operating cash flow in the second half of 2026.